newsfilter
← Latest News
GlobeNewswire·

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs